Lidocaïne Kabi (Lidocaine Hydrochloride Monohydrate)

Lidocaine Hydrochloride is used to provide local anesthesia and analgesia across several clinical pathways.

• Local anesthesia: produces reversible loss of sensation in targeted tissue for surgical or diagnostic procedures.
• Epidural analgesia: delivers pain relief during labor, surgery, or postoperative period by blocking nerve transmission in the epidural space.
• Ventricular arrhythmias: stabilizes cardiac electrical activity in the acute management of life‑threatening ventricular tachycardia or fibrillation.

• Lidocaine blocks voltage‑gated sodium channels on neuronal and cardiac cell membranes, preventing the rapid influx of sodium ions required for depolarization. This inhibition halts the initiation and propagation of nerve impulses, producing local loss of sensation and reducing abnormal cardiac excitability.

Lidocaine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Tingling or numbness at the injection site
• Light‑headedness or dizziness
• Nausea or vomiting
• Metallic taste in the mouth

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis)
• Cardiac conduction disturbances (bradycardia, heart block)
• Central nervous system toxicity (seizures, loss of consciousness)
• Methemoglobinemia (rare)

When using Lidocaïne Kabi, clinicians should observe several safety measures.

• Patient assessment: evaluate cardiac history and conduction abnormalities before use.
• Dose titration: adjust dosage in patients with hepatic impairment or reduced plasma protein binding.
• Monitoring: observe for signs of CNS toxicity during high‑dose or rapid administration.
• Drug interactions: avoid concurrent use with class I antiarrhythmics or other sodium channel blockers.
• Pregnancy and lactation: use only if benefit outweighs potential risk; data limited.
• Store at ambient temperature: keep below 25 °C, protect from light and moisture, retain in original container.

Lidocaine can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Class I antiarrhythmic agents (e.g., quinidine, procainamide): additive cardiac conduction effects.
• Beta‑blockers (e.g., propranolol) in high doses: increased risk of bradycardia.
• CYP3A4 inhibitors (e.g., ketoconazole): may raise lidocaine plasma levels.

Moderate Interactions (Monitor Closely)

• Calcium channel blockers (e.g., verapamil): potential for enhanced hypotension.
• Diuretics (e.g., furosemide): may alter plasma protein binding.
• General anesthetics (e.g., propofol): additive CNS depression.